van der Linden M C, van Erp E J, Ruijs G J, Holm J P
Department of Obstetrics and Gynaecology, Municipal Hospital Leyenburg, The Hogue, The Netherlands.
Eur J Obstet Gynecol Reprod Biol. 1993 Jul;50(2):141-5. doi: 10.1016/0028-2243(93)90178-f.
A prospective, randomized, open study was performed in 199 patients at the Leyenburg Hospital comparing amoxycillin/clavulanate (AMX/CL) with cefuroxime plus metronidazole (CR/MN) in the prophylaxis of infection following gynaecological surgery. AMX/CL was given as a single dose of 2200 mg i.v. at the start of the operation. CR/MN, 750/500 mg i.v. was administered 3 times within 24 h, beginning at the start of the operation. The study group consisted of patients undergoing either a vaginal hysterectomy, a vaginal hysterectomy with cysto/rectocele repair or a secondary caesarean section. There were no statistically significant differences in demographic characteristics, duration of surgery or anaesthetic method between the two groups. Postoperatively, 10.6% of patients developed a urinary tract infection, and febrile temperatures were found in 9.0% of patients. There were no statistically significant differences between the two treatment groups. Other complications were found in less than 1% of the study population, equally distributed between the two regimens. In this study there was a low overall percentage of infection after gynaecological surgery. AMX/CL was as effective as CR/MN as a perioperative prophylactic treatment and has the dual advantage of a single dose and lower cost.
在莱延堡医院对199例患者进行了一项前瞻性、随机、开放性研究,比较阿莫西林/克拉维酸(AMX/CL)与头孢呋辛加甲硝唑(CR/MN)在妇科手术后预防感染方面的效果。AMX/CL在手术开始时静脉注射单剂量2200毫克。CR/MN,750/500毫克静脉注射,在24小时内分3次给药,从手术开始时开始。研究组包括接受阴道子宫切除术、阴道子宫切除术加膀胱/直肠膨出修补术或二次剖宫产的患者。两组在人口统计学特征、手术时间或麻醉方法方面无统计学显著差异。术后,10.6%的患者发生尿路感染,9.0%的患者出现发热。两个治疗组之间无统计学显著差异。其他并发症在不到1%的研究人群中发现,在两种治疗方案中分布均匀。在本研究中,妇科手术后感染的总体百分比很低。AMX/CL作为围手术期预防性治疗与CR/MN一样有效,并且具有单剂量和低成本的双重优势。